A new paradigm for developing drugs in children: Atomoxetine as a model

Archives of Disease in Childhood

Volumn 90, Issue SUPPL. 1, 2005, Pages

  Prasad, S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; ETHICS; HUMAN; INTERPERSONAL COMMUNICATION; NONHUMAN; PEDIATRICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG DESIGN; HUMANS; PROPYLAMINES;

EID: 13244277705     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2004.059378     Document Type: Review

References (24)

1. Committee on Safety of Medicines. Use of selective serotonin reuptake inhibitors (SSRIs) in children and adolescents with major depressive disorder (MDD), Available at www.mhra.gov.uk (accessed 16 November 2004).
2. Ramchandani P. Treatment of major depressive disorder in children and adolescents. BMJ 2004;328:3-4.
3. Simeon JG, Dinicola VF, Ferguson HB, et al. Adolescent depression: a placebo-controlled fluoxetine study and follow up. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:791-5.
4. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-7.
5. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents; a placebo-controlled, randomised clinical trial. J Am Acad Child Adolesc Psychiatry 2002;41:1205-15.
6. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of noradrenaline and dopamine in the prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711.
7. Tizzano JP, Childers DH, Griffey KI, et al. Non-clinicol pediatric testing of tomoxetine: toxicity, reproduction/fertility and neurobehavioural studies in young Fischer 344 rats. Neurotoxicology and Teratology 2001;23:283-98.
8. US Food and Drug Administration. Additional safeguards for children on clinical investigation of FDA-regulated products, 21CFR Parts 50 and 56, Federal Register, April 24 2001;66(79):20589-600.
9. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo-controlled study of desipramine in the treatment of ADD: 1. Efficacy. J Am Acad Child Adolesc Psychiatry 1989;28:777-84.
10. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of atomoxetine in adults with attention-deficit/hyperactivity disorder. Am J Psychiatry 1998;155:693-5.
11. Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of tomoxetine in pediatric attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:167-70.
12. Spencer T, Biederman J, Heiligenstein J, et al. An open-label dose-ranging study of tomoxetine in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:251-6.
13. Spencer T, Heiligenstein JH, Biederman J, et al. Results of two proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-7.
14. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomised, placebo-controlled, dose response study. Pediatrics 2001;108:e83.
15. Allen AJ, Kelsey D, Summer C, et al. Once daily treatment in the management of ADHD-continuous symptom relief. European Neuropsychopharmacol 2003;13(Suppl 4):S454-5.
16. Weiss M, Tannock R, Kratochvil C, et al. Placebo-controlled study of once-daily atomoxetine in the school setting. European Neuropsychopharmacol 2003;13(suppl 4):S456-7.
17. Michelson D, Allen AJ, Busner J, et al. Once daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomised, placebo-controlled study. Am J Psychiatry 2002;159:1896-901.
18. Harpin V, Prasad S, Michelson M. Atomoxetine in the long-term prevention of relapse of ADHD. Paper presented at the Royal College of Paediatrics and Child Health Annual Spring Meeting, 29 March, 2004.
19. Mooney P, Barton J, Prasad S. The effect of atomoxetine hydrochloride on executive functioning of children with ADHD: a pilot study. Paper presented at the European Society of Child and Adolescent Psychiatry Annual Meeting, Paris, 28 September-1 October, 2003.
20. Newcorn J, Michelson D, Spencer T, et al. Atomoxetine treatment in children and adolescents in ADHD and comorbid ODD. Paper presented at European Society of Child and Adolescent Psychiatry, Paris, 28 September-1 October, 2003.
21. Harpin V, Prasad S, Thomason C, et al. Changes in quality of life in patients with ADHD after atomoxetine treatment. Paper presented at European Academy of Childhood Disability Annual Meeting, Oslo, 2-4 October, 2003.
22. Wernicke J, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents and adults. Drug Saf 2003;26:729-40.
23. Michelson D, Spencer T, Ruff D, et al. Long-term effects of atomoxefine on growth in children with ADHD. Paper presented at the 50th Anniversary Meeting of the American Academy of Child & Adolescent Psychiatry, Miami, Florida, 14-19 October, 2003.
24. Barton J, Prasad S, Buitelaar JK, et al. 10-week open-label acute treatment with atomoxetine in non-North American children with ADHD. Poster presented at the Royal College of Psychiatrists Annual General Meeting, Edinburgh, June, 2003.